Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-N(omega)-nitroarginine-(4R)-amino-L-proline amide is a synthetic small molecule belonging to the class of proline derivatives. It is an experimental compound primarily used as a research tool. The drug acts as an inhibitor of nitric oxide synthase (NOS), thereby reducing the production of nitric oxide, a key signaling molecule involved in vasodilation and neurotransmission. By inhibiting NOS isoforms—including neuronal (NOS1), inducible (NOS2), and endothelial (NOS3)—this compound serves as a valuable probe for studying the physiological and pathophysiological roles of nitric oxide in cardiovascular, neurological, and inflammatory processes[6][10]. There are no approved clinical indications or marketed formulations for this agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-N(omega)-nitroarginine-(4R)-amino-L-proline amide.